Depressive Disorder and Anxiety Disorders
Conditions
Keywords
Social Anxiety Disorder, brain imaging, Positron Emission Tomography, antidepressant
Brief summary
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging readouts (i.e., WAT(Wave Analysis Technology) PET(Positron Emission Tomography)), after one or eight weeks of treatment. The effect of paroxetine alone after one or eight weeks of treatment will also be measured.
Detailed description
A double-blind, double dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of vestipitant and paroxetine in combination or paroxetine alone on regional cerebral blood flow during a public speaking test in subjects affected by social anxiety disorder.
Interventions
DRUGvestipitant
DRUGparoxetine
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Social phobic ambulatory subjects, defined according to DSM-IV criteria. * Must be capable of giving informed consent and can comply with the study requirements. * Women of childbearing potential must agree to acceptable method of birth control.
Exclusion criteria
* Primary diagnosis within the past 6 months of other psychiatric conditions such as major depression or another anxiety disorder. * Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type. * Subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months. * Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine). * Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG) findings.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess, by mean of Positron Emission Tomography, the degree of regional Cerebral Blood Flow in different brain regions involved in the emotional brain circuit during public speaking task before treatment and after eight weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess symptomatic and physiological measures of anxiety induced by the public speaking task and social anxiety symptoms during eight weeks of treatment. To evaluate safety, tolerability and the effect on sexual function of treatment. | — |
Countries
Sweden
Outcome results
None listed